Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company reports developments in lens-based refractive surgery through its EVO family of Implantable Collamer® Lenses, including EVO ICL™ for vision correction. The company designs, manufactures and sells implantable lenses for the eye and related delivery systems, with ICL products forming the core of its revenue base.
Recurring updates cover quarterly and annual results, preliminary sales, strategic-plan progress, market trends in China, the Americas and other international markets, regulatory indication changes, clinical evidence for EVO ICL, product adoption milestones, board and executive transitions, and shareholder voting or governance matters.
STAAR Surgical Company (NASDAQ: STAA) will release its financial results for the third quarter ended October 2, 2020, on November 4, 2020, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results. Interested parties can access the call at 833-350-1429 (domestic) or 647-689-6661 (international). A replay and archived webcast will be available shortly after the call. STAAR specializes in implantable lenses and has marketed over 1,000,000 Visian® ICLs worldwide.